A O
new O
vitamin B
D I
analogue O
, O
22 B
- I
oxacalcitriol I
( O
OCT B
) O
, O
has O
been O
shown O
to O
have O
promising O
characteristics O
. O

METHODS O
: O
Puromycin B
aminonucleoside I
( O
PAN B
) O
was O
administered O
to O
Sprague O
Dawley O
rats O
to O
induce O
proteinuria O
. O

Maximal O
platelet O
aggregation O
induced O
by O
6 O
microM O
of O
adenosine B
diphosphate I
decreased O
after O
administration O
of O
ketoprofen B
. O

Nitric B
oxide I
synthase O
expression O
in O
the O
course O
of O
lead B
- O
induced O
hypertension O
. O

Male O
Sprague O
- O
Dawley O
rats O
were O
randomly O
assigned O
to O
a O
lead B
- O
treated O
group O
( O
given O
lead B
acetate I
, O
100 O
ppm O
, O
in O
drinking O
water O
and O
regular O
rat O
chow O
) O
, O
a O
group O
given O
lead B
and O
vitamin B
E I
- O
fortified O
chow O
, O
or O
a O
normal O
control O
group O
given O
either O
regular O
food O
and O
water O
or O
vitamin B
E I
- O
fortified O
food O
for O
12 O
weeks O
. O

Male O
Sprague O
- O
Dawley O
rats O
were O
randomly O
assigned O
to O
a O
lead B
- O
treated O
group O
( O
given O
lead B
acetate I
, O
100 O
ppm O
, O
in O
drinking O
water O
and O
regular O
rat O
chow O
) O
, O
a O
group O
given O
lead B
and O
vitamin B
E I
- O
fortified O
chow O
, O
or O
a O
normal O
control O
group O
given O
either O
regular O
food O
and O
water O
or O
vitamin B
E I
- O
fortified O
food O
for O
12 O
weeks O
. O

Male O
Sprague O
- O
Dawley O
rats O
were O
randomly O
assigned O
to O
a O
lead B
- O
treated O
group O
( O
given O
lead B
acetate I
, O
100 O
ppm O
, O
in O
drinking O
water O
and O
regular O
rat O
chow O
) O
, O
a O
group O
given O
lead B
and O
vitamin B
E I
- O
fortified O
chow O
, O
or O
a O
normal O
control O
group O
given O
either O
regular O
food O
and O
water O
or O
vitamin B
E I
- O
fortified O
food O
for O
12 O
weeks O
. O

Vitamin B
E I
supplementation O
ameliorated O
hypertension O
, O
lowered O
plasma O
MDA B
concentration O
, O
and O
raised O
urinary O
NOx O
excretion O
while O
significantly O
lowering O
vascular O
, O
but O
not O
renal O
, O
tissue O
eNOS O
and O
iNOS O
expression O
. O

Vitamin B
E I
supplementation O
had O
no O
effect O
on O
either O
blood O
pressure O
, O
plasma O
MDA B
, O
or O
NOS O
expression O
in O
the O
control O
group O
. O

Glyceryl B
trinitrate I
induces O
attacks O
of O
migraine O
without O
aura O
in O
sufferers O
of O
migraine O
with O
aura O
. O

In O
recent O
years O
, O
increasing O
evidence O
has O
suggested O
that O
the O
messenger O
molecule O
nitric B
oxide I
( O
NO B
) O
is O
involved O
in O
pain O
mechanisms O
of O
migraine O
without O
aura O
. O

In O
order O
to O
clarify O
whether O
the O
same O
is O
true O
for O
migraine O
with O
aura O
, O
in O
the O
present O
study O
we O
examined O
the O
headache O
response O
to O
intravenous O
infusion O
of O
glyceryl B
trinitrate I
( O
GTN B
) O
( O
0 O
. O
5 O
microg O
/ O
kg O
/ O
min O
for O
20 O
min O
) O
in O
12 O
sufferers O
of O
migraine O
with O
aura O
. O

Rapid O
reversal O
of O
life O
- O
threatening O
diltiazem B
- O
induced O
tetany O
with O
calcium B
chloride I
. O

The O
administration O
of O
calcium B
chloride I
rapidly O
resolved O
the O
patient O
' O
s O
tetany O
with O
prompt O
recovery O
of O
respiratory O
function O
, O
averting O
the O
need O
for O
more O
aggressive O
airway O
management O
and O
ventilatory O
support O
. O

The O
emergency O
physician O
should O
be O
aware O
that O
life O
- O
threatening O
tetany O
may O
accompany O
the O
administration O
of O
intravenous O
diltiazem B
and O
that O
calcium B
chloride I
may O
be O
a O
rapid O
and O
effective O
remedy O
. O

Contribution O
of O
sodium B
valproate I
to O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
. O

We O
report O
the O
case O
of O
a O
62 O
- O
year O
- O
old O
man O
who O
was O
administered O
sodium B
valproate I
( O
VPA B
) O
and O
who O
subsequently O
developed O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
( O
SIADH O
) O
. O

Association O
of O
nitric B
oxide I
production O
and O
apoptosis O
in O
a O
model O
of O
experimental O
nephropathy O
. O

BACKGROUND O
: O
In O
recent O
studies O
increased O
amounts O
of O
nitric B
oxide I
( O
NO B
) O
and O
apoptosis O
have O
been O
implicated O
in O
various O
pathological O
conditions O
in O
the O
kidney O
. O

Sodium B
thiopenthal I
was O
administered O
intraperitoneally O
into O
male O
rats O
pre O
- O
treated O
with O
melatonin B
( O
0 O
. O
05 O
, O
0 O
. O
5 O
, O
5 O
and O
50 O
mg O
/ O
kg O
) O
. O

The O
effects O
of O
N B
- I
nitro I
- I
L I
- I
arginine I
- I
methyl I
ester I
( O
L B
- I
NAME I
) O
a O
nitric B
oxide I
( O
NO B
) O
synthase O
inhibitor O
and O
L B
- I
arginine I
, O
a O
NO B
precursor O
, O
were O
investigated O
on O
lidocaine B
- O
induced O
convulsions O
. O

Calcitonin O
gene O
- O
related O
peptide O
levels O
during O
nitric B
oxide I
- O
induced O
headache O
in O
patients O
with O
chronic O
tension O
- O
type O
headache O
. O

It O
has O
been O
proposed O
that O
nitric B
oxide I
( O
NO B
) O
induced O
headache O
in O
primary O
headaches O
may O
be O
associated O
with O
release O
of O
calcitonin O
gene O
- O
related O
peptide O
( O
CGRP O
) O
. O

In O
the O
present O
study O
we O
aimed O
to O
investigate O
plasma O
levels O
of O
CGRP O
during O
headache O
induced O
by O
the O
NO B
donor O
glyceryl B
trinitrate I
( O
GTN B
) O
in O
16 O
patients O
with O
chronic O
tension O
- O
type O
headache O
and O
16 O
healthy O
controls O
. O

We O
report O
a O
patient O
who O
developed O
cholestatic O
jaundice O
shortly O
after O
initiation O
of O
treatment O
with O
metformin B
hydrochloride I
. O

Metformin B
hydrochloride I
was O
discontinued O
, O
and O
the O
patient O
' O
s O
jaundice O
resolved O
slowly O
over O
a O
period O
of O
several O
months O
. O

Amphotericin B
B I
- O
induced O
seizures O
in O
a O
patient O
with O
AIDS O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
multiple O
episodes O
of O
seizure O
activity O
in O
an O
AIDS O
patent O
following O
amphotericin B
B I
infusion O
. O

CASE O
SUMMARY O
: O
A O
46 O
- O
year O
- O
old O
African O
- O
American O
man O
experienced O
recurrent O
grand O
mal O
seizures O
during O
intravenous O
infusion O
of O
amphotericin B
B I
, O
then O
petit O
mal O
seizures O
as O
the O
infusion O
was O
stopped O
and O
the O
drug O
concentrations O
decreased O
with O
time O
. O

Despite O
administration O
of O
phenytoin B
and O
lorazepam B
, O
the O
seizures O
persisted O
and O
occurred O
only O
during O
amphotercin B
B I
administration O
. O

The O
time O
course O
of O
events O
suggested O
that O
amphotericin B
B I
was O
the O
cause O
of O
the O
seizures O
in O
this O
AIDS O
patient O
. O

CONCLUSIONS O
: O
Amphotericin B
B I
seems O
to O
be O
the O
probable O
cause O
of O
the O
seizures O
. O

To O
date O
, O
only O
three O
cases O
of O
seizures O
associated O
with O
amphotericin B
B I
have O
been O
reported O
in O
the O
literature O
, O
but O
healthcare O
providers O
should O
be O
aware O
of O
the O
potential O
for O
this O
rare O
adverse O
effect O
. O

Sirolimus B
and O
mycophenolate B
mofetil I
for O
calcineurin O
- O
free O
immunosuppression O
in O
renal O
transplant O
recipients O
. O

Two O
recently O
available O
immunosuppressive O
agents O
, O
mycophenolate B
mofetil I
and O
sirolimus B
( O
rapamycin B
) O
, O
have O
no O
nephrotoxicity O
. O

We O
compared O
these O
results O
with O
those O
previously O
obtained O
with O
kainic B
acid I
( O
KA B
) O
, O
a O
potent O
glutamate B
agonist O
. O

Steroid B
structure O
and O
pharmacological O
properties O
determine O
the O
anti O
- O
amnesic O
effects O
of O
pregnenolone B
sulphate I
in O
the O
passive O
avoidance O
task O
in O
rats O
. O

Pregnenolone B
sulphate I
( O
PREGS B
) O
has O
generated O
interest O
as O
one O
of O
the O
most O
potent O
memory O
- O
enhancing O
neurosteroids O
to O
be O
examined O
in O
rodent O
learning O
studies O
, O
with O
particular O
importance O
in O
the O
ageing O
process O
. O

The O
results O
show O
that O
, O
unlike O
PREGS B
, O
11 B
- I
ketopregnenolone I
sulphate I
and O
epipregnanolone B
sulphate I
failed O
to O
block O
the O
effect O
of O
scopolamine B
, O
suggesting O
that O
altering O
the O
modulation O
of O
NMDA B
receptors O
diminishes O
the O
memory O
- O
enhancing O
effects O
of O
PREGS B
. O

Spironolactone B
: O
is O
it O
a O
novel O
drug O
for O
the O
prevention O
of O
amphotericin B
B I
- O
related O
hypokalemia O
in O
cancer O
patients O
? O

OBJECTIVE O
: O
Nephrotoxicity O
is O
the O
major O
adverse O
effect O
of O
amphotericin B
B I
( O
AmB B
) O
, O
often O
limiting O
administration O
of O
full O
dosage O
. O

These O
factors O
can O
lead O
to O
the O
development O
of O
calcium B
phosphate I
nephrolithiasis O
. O

Unfractionated B
heparin I
( O
UH B
) O
is O
currently O
the O
substitute O
for O
selected O
patients O
. O

Immunohistochemical O
study O
on O
inducible O
type O
of O
nitric B
oxide I
( O
iNOS O
) O
, O
basic O
fibroblast O
growth O
factor O
( O
bFGF O
) O
and O
tumor O
growth O
factor O
- O
beta1 O
( O
TGF O
- O
beta1 O
) O
in O
arteritis O
induced O
in O
rats O
by O
fenoldopam B
and O
theophylline B
, O
vasodilators O
. O

Arteritis O
induced O
in O
rats O
by O
vasodilators O
, O
fenoldopam B
and O
theophylline B
, O
was O
examined O
immunohistochemically O
for O
expressions O
of O
inducible O
type O
of O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
basic O
fibroblast O
growth O
factor O
( O
bFGF O
) O
and O
tumor O
growth O
factor O
- O
beta1 O
( O
TGF O
- O
beta1 O
) O
. O

Similarly O
, O
when O
the O
P450 O
- O
mediated O
metabolism O
of O
lindane B
was O
blocked O
by O
cobalt B
chloride I
incidence O
of O
convulsions O
was O
increased O
in O
animals O
treated O
with O
lindane B
indicating O
that O
lindane B
per O
se O
or O
its O
metabolites O
formed O
by O
PB O
or O
ethanol B
inducible O
P450 O
isoenzymes O
are O
involved O
in O
its O
neurobehavioral O
toxicity O
. O

Absolute O
and O
attributable O
risk O
of O
venous O
thromboembolism O
in O
women O
on O
combined O
cyproterone B
acetate I
and O
ethinylestradiol B
. O

OBJECTIVE O
: O
To O
achieve O
absolute O
risk O
estimates O
of O
venous O
thromboembolism O
( O
VTE O
) O
among O
women O
on O
cyproterone B
acetate I
plus O
ethinylestradiol B
( O
CPA B
/ O
EE B
) O
, O
and O
among O
women O
on O
combined B
oral I
contraceptives I
( O
COCs B
) O
. O

Comparison O
of O
developmental O
toxicology O
of O
aspirin B
( O
acetylsalicylic B
acid I
) O
in O
rats O
using O
selected O
dosing O
paradigms O
. O

Aspirin B
( O
acetylsalicylic B
acid I
[ O
ASA B
] O
) O
, O
an O
irreversible O
cyclooxygenase O
1 O
and O
2 O
inhibitor O
, O
induces O
developmental O
anomalies O
when O
administered O
to O
Wistar O
rats O
on O
gestational O
day O
( O
GD O
) O
9 O
, O
10 O
, O
or O
11 O
( O
Kimmel O
CA O
, O
Wilson O
JG O
, O
Schumacher O
HJ O
. O
Teratology O
4 O
: O
15 O
- O
24 O
, O
1971 O
) O
. O

Thromboembolic O
and O
other O
complications O
of O
oral B
contraceptive I
therapy O
in O
relationship O
to O
pretreatment O
levels O
of O
blood O
coagulation O
factors O
: O
summary O
report O
of O
a O
ten O
- O
year O
study O
. O

During O
a O
ten O
- O
year O
period O
, O
348 O
women O
were O
studied O
for O
a O
total O
of O
5 O
, O
877 O
patient O
months O
in O
four O
separate O
studies O
relating O
oral B
contraceptives I
to O
changes O
in O
hematologic O
parameters O
. O

It O
appears O
from O
these O
data O
that O
hematologic O
work O
- O
ups O
may O
be O
useful O
in O
women O
who O
are O
about O
to O
start O
long O
- O
term O
oral B
contraceptive I
therapy O
. O

Increased O
expression O
and O
apical O
targeting O
of O
renal O
ENaC O
subunits O
in O
puromycin B
aminonucleoside I
- O
induced O
nephrotic O
syndrome O
in O
rats O
. O

An O
experimental O
group O
of O
rats O
was O
treated O
with O
puromycin B
aminonucleoside I
( O
PAN B
; O
180 O
mg O
/ O
kg O
iv O
) O
, O
whereas O
the O
control O
group O
received O
only O
vehicle O
. O

Does O
supplemental O
vitamin B
C I
increase O
cardiovascular O
disease O
risk O
in O
women O
with O
diabetes O
? O

BACKGROUND O
: O
Vitamin B
C I
acts O
as O
a O
potent O
antioxidant O
; O
however O
, O
it O
can O
also O
be O
a O
prooxidant O
and O
glycate O
protein O
under O
certain O
circumstances O
in O
vitro O
. O

These O
observations O
led O
us O
to O
hypothesize O
that O
a O
high O
intake O
of O
vitamin B
C I
in O
diabetic O
persons O
might O
promote O
atherosclerosis O
. O

OBJECTIVE O
: O
The O
objective O
was O
to O
examine O
the O
relation O
between O
vitamin B
C I
intake O
and O
mortality O
from O
cardiovascular O
disease O
. O

DESIGN O
: O
We O
studied O
the O
relation O
between O
vitamin B
C I
intake O
and O
mortality O
from O
total O
cardiovascular O
disease O
( O
n O
= O
281 O
) O
, O
coronary O
artery O
disease O
( O
n O
= O
175 O
) O
, O
and O
stroke O
( O
n O
= O
57 O
) O
in O
1923 O
postmenopausal O
women O
who O
reported O
being O
diabetic O
at O
baseline O
. O

RESULTS O
: O
After O
adjustment O
for O
cardiovascular O
disease O
risk O
factors O
, O
type O
of O
diabetes O
medication O
used O
, O
duration O
of O
diabetes O
, O
and O
intakes O
of O
folate B
, O
vitamin B
E I
, O
and O
beta B
- I
carotene I
, O
the O
adjusted O
relative O
risks O
of O
total O
cardiovascular O
disease O
mortality O
were O
1 O
. O
0 O
, O
0 O
. O
97 O
, O
1 O
. O
11 O
, O
1 O
. O
47 O
, O
and O
1 O
. O
84 O
( O
P O
for O
trend O
< O
0 O
. O
01 O
) O
across O
quintiles O
of O
total O
vitamin B
C I
intake O
from O
food O
and O
supplements O
. O

RESULTS O
: O
After O
adjustment O
for O
cardiovascular O
disease O
risk O
factors O
, O
type O
of O
diabetes O
medication O
used O
, O
duration O
of O
diabetes O
, O
and O
intakes O
of O
folate B
, O
vitamin B
E I
, O
and O
beta B
- I
carotene I
, O
the O
adjusted O
relative O
risks O
of O
total O
cardiovascular O
disease O
mortality O
were O
1 O
. O
0 O
, O
0 O
. O
97 O
, O
1 O
. O
11 O
, O
1 O
. O
47 O
, O
and O
1 O
. O
84 O
( O
P O
for O
trend O
< O
0 O
. O
01 O
) O
across O
quintiles O
of O
total O
vitamin B
C I
intake O
from O
food O
and O
supplements O
. O

When O
dietary O
and O
supplemental O
vitamin B
C I
were O
analyzed O
separately O
, O
only O
supplemental O
vitamin B
C I
showed O
a O
positive O
association O
with O
mortality O
endpoints O
. O

When O
dietary O
and O
supplemental O
vitamin B
C I
were O
analyzed O
separately O
, O
only O
supplemental O
vitamin B
C I
showed O
a O
positive O
association O
with O
mortality O
endpoints O
. O

Vitamin B
C I
intake O
was O
unrelated O
to O
mortality O
from O
cardiovascular O
disease O
in O
the O
nondiabetic O
subjects O
at O
baseline O
. O

CONCLUSION O
: O
A O
high O
vitamin B
C I
intake O
from O
supplements O
is O
associated O
with O
an O
increased O
risk O
of O
cardiovascular O
disease O
mortality O
in O
postmenopausal O
women O
with O
diabetes O
. O

With O
this O
model O
, O
we O
were O
able O
to O
identify O
diffuse O
cortical O
hypoxia O
in O
the O
puromycin B
aminonucleoside I
- O
induced O
nephrotic O
syndrome O
and O
focal O
and O
segmental O
hypoxia O
in O
the O
remnant O
kidney O
model O
. O

Expression O
of O
the O
hypoxia O
- O
responsive O
transgene O
increased O
throughout O
the O
observation O
period O
, O
reaching O
2 O
. O
2 O
- O
fold O
at O
2 O
weeks O
in O
the O
puromycin B
aminonucleoside I
model O
and O
2 O
. O
6 O
- O
fold O
at O
4 O
weeks O
in O
the O
remnant O
kidney O
model O
, O
whereas O
that O
of O
vascular O
endothelial O
growth O
factor O
showed O
a O
mild O
decrease O
, O
reflecting O
distinct O
behaviors O
of O
the O
two O
genes O
. O

Valproic B
acid I
I O
: O
time O
course O
of O
lipid O
peroxidation O
biomarkers O
, O
liver O
toxicity O
, O
and O
valproic B
acid I
metabolite O
levels O
in O
rats O
. O

Valproic B
acid I
I O
: O
time O
course O
of O
lipid O
peroxidation O
biomarkers O
, O
liver O
toxicity O
, O
and O
valproic B
acid I
metabolite O
levels O
in O
rats O
. O

A O
single O
dose O
of O
valproic B
acid I
( O
VPA B
) O
, O
which O
is O
a O
widely O
used O
antiepileptic O
drug O
, O
is O
associated O
with O
oxidative O
stress O
in O
rats O
, O
as O
recently O
demonstrated O
by O
elevated O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
isoprostane I
( O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
) O
. O

Oxidative O
stress O
was O
assessed O
by O
determining O
plasma O
and O
liver O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
, O
lipid B
hydroperoxides I
( O
LPO B
) O
, O
and O
thiobarbituric B
acid I
reactive I
substances I
( O
TBARs B
) O
. O

Calcium B
carbonate I
toxicity O
: O
the O
updated O
milk O
- O
alkali O
syndrome O
; O
report O
of O
3 O
cases O
and O
review O
of O
the O
literature O
. O

OBJECTIVE O
: O
To O
describe O
3 O
patients O
with O
calcium B
carbonate I
- O
induced O
hypercalcemia O
and O
gain O
insights O
into O
the O
cause O
and O
management O
of O
the O
milk O
- O
alkali O
syndrome O
. O

Of O
the O
3 O
patients O
, O
2 O
were O
ingesting O
acceptable O
doses O
of O
elemental O
calcium B
( O
1 O
g O
and O
2 O
g O
daily O
, O
respectively O
) O
in O
the O
form O
of O
calcium B
carbonate I
. O

CONCLUSION O
: O
Milk O
- O
alkali O
syndrome O
may O
be O
a O
common O
cause O
of O
unexplained O
hypercalcemia O
and O
can O
be O
precipitated O
by O
small O
amounts O
of O
orally O
ingested O
calcium B
carbonate I
in O
susceptible O
persons O
. O

Treatment O
with O
hydration O
, O
furosemide B
, O
and O
discontinuation O
of O
the O
calcium B
and O
vitamin B
D I
source O
is O
adequate O
. O

The O
direct O
nephrotoxic O
effects O
of O
a O
single O
dose O
of O
15 O
mg O
of O
suprofen B
were O
compared O
in O
the O
recirculating O
isolated O
rat O
kidney O
perfused O
with O
cell O
- O
free O
buffer O
with O
or O
without O
the O
addition O
of O
5 O
mg O
/ O
dL O
of O
uric B
acid I
. O

In O
contrast O
, O
a O
significant O
decline O
in O
glomerular O
filtration O
rate O
was O
found O
after O
the O
introduction O
of O
suprofen B
to O
the O
kidney O
perfused O
with O
uric B
acid I
; O
no O
changes O
were O
found O
with O
suprofen B
in O
the O
absence O
of O
uric B
acid I
. O

In O
contrast O
, O
a O
significant O
decline O
in O
glomerular O
filtration O
rate O
was O
found O
after O
the O
introduction O
of O
suprofen B
to O
the O
kidney O
perfused O
with O
uric B
acid I
; O
no O
changes O
were O
found O
with O
suprofen B
in O
the O
absence O
of O
uric B
acid I
. O

A O
significant O
decrease O
in O
the O
baseline O
excretion O
rate O
of O
uric B
acid I
was O
found O
in O
rats O
given O
suprofen B
, O
compared O
with O
drug O
- O
free O
controls O
. O

However O
, O
the O
fractional O
excretion O
of O
uric B
acid I
was O
unchanged O
between O
the O
groups O
over O
the O
experimental O
period O
. O

In O
summary O
, O
suprofen B
causes O
acute O
declines O
in O
renal O
function O
, O
most O
likely O
by O
directly O
altering O
the O
intrarenal O
distribution O
of O
uric B
acid I
. O

Subcutaneous O
injection O
of O
ISPH B
( O
200 O
mg O
/ O
kg O
body O
weight O
in O
1 O
ml O
saline O
) O
to O
rats O
for O
2 O
consecutive O
days O
caused O
myocardial O
damage O
in O
rat O
heart O
, O
which O
was O
determined O
by O
the O
increased O
activity O
of O
serum O
lactate B
dehydrogenase O
( O
LDH O
) O
and O
creatine B
phosphokinase O
isoenzymes O
( O
CK O
- O
MB O
) O
, O
increased O
uric B
acid I
level O
and O
reduced O
plasma O
iron B
binding O
capacity O
. O

The O
heart O
tissue O
antioxidant O
enzymes O
such O
as O
superoxide B
dismutase O
, O
catalase O
, O
glutathione B
peroxidase O
, O
glutathione B
transferase O
and O
glutathione B
reductase O
activities O
, O
non O
- O
enzymic O
antioxidants O
such O
as O
cerruloplasmin O
, O
Vitamin B
C I
, O
Vitamin B
E I
and O
glutathione B
levels O
were O
altered O
in O
MI O
rats O
. O

The O
heart O
tissue O
antioxidant O
enzymes O
such O
as O
superoxide B
dismutase O
, O
catalase O
, O
glutathione B
peroxidase O
, O
glutathione B
transferase O
and O
glutathione B
reductase O
activities O
, O
non O
- O
enzymic O
antioxidants O
such O
as O
cerruloplasmin O
, O
Vitamin B
C I
, O
Vitamin B
E I
and O
glutathione B
levels O
were O
altered O
in O
MI O
rats O
. O

Upon O
pretreatment O
with O
mangiferin B
( O
100 O
mg O
/ O
kg O
body O
weight O
suspended O
in O
2 O
ml O
of O
dimethyl B
sulphoxide I
) O
given O
intraperitoneally O
for O
28 O
days O
to O
MI O
rats O
protected O
the O
above O
- O
mentioned O
parameters O
to O
fall O
from O
the O
normal O
levels O
. O

Cardiovascular O
risk O
with O
cyclooxygenase B
inhibitors I
: O
general O
problem O
with O
substance O
specific O
differences O
? O

Randomised O
clinical O
trials O
and O
observational O
studies O
have O
shown O
an O
increased O
risk O
of O
myocardial O
infarction O
, O
stroke O
, O
hypertension O
and O
heart O
failure O
during O
treatment O
with O
cyclooxygenase B
inhibitors I
. O

Cyclooxygenase B
inhibitors I
cause O
complex O
changes O
in O
renal O
, O
vascular O
and O
cardiac O
prostanoid O
profiles O
thereby O
increasing O
vascular O
resistance O
and O
fluid O
retention O
. O

A O
comparison O
of O
individual O
selective O
and O
unselective O
cyclooxygenase B
inhibitors I
suggests O
substance O
- O
specific O
differences O
, O
which O
may O
depend O
on O
differences O
in O
pharmacokinetic O
parameters O
or O
inhibitory O
potency O
and O
may O
be O
contributed O
by O
prostaglandin B
- O
independent O
effects O
. O

Peripheral O
neuropathy O
caused O
by O
high O
- O
dose O
cytosine B
arabinoside I
treatment O
in O
a O
patient O
with O
acute O
myeloid O
leukemia O
. O

The O
central O
nervous O
system O
toxicity O
of O
high O
- O
dose O
cytosine B
arabinoside I
is O
well O
recognized O
, O
but O
the O
toxicity O
of O
cytosine B
arabinoside I
in O
the O
peripheral O
nervous O
system O
has O
been O
infrequently O
reported O
. O

The O
central O
nervous O
system O
toxicity O
of O
high O
- O
dose O
cytosine B
arabinoside I
is O
well O
recognized O
, O
but O
the O
toxicity O
of O
cytosine B
arabinoside I
in O
the O
peripheral O
nervous O
system O
has O
been O
infrequently O
reported O
. O

After O
he O
achieved O
complete O
remission O
, O
he O
received O
high O
- O
dose O
cytosine B
arabinoside I
treatment O
( O
2 O
g O
/ O
m2 O
twice O
a O
day O
for O
5 O
days O
; O
total O
, O
20 O
g O
/ O
m2 O
) O
as O
consolidation O
therapy O
. O

The O
first O
course O
of O
high O
- O
dose O
cytosine B
arabinoside I
resulted O
in O
no O
unusual O
symptoms O
, O
but O
on O
day O
21 O
of O
the O
second O
course O
of O
treatment O
, O
the O
patient O
complained O
of O
numbness O
in O
his O
right O
foot O
. O

Although O
the O
mechanisms O
of O
peripheral O
neuropathy O
are O
still O
unclear O
, O
high O
- O
dose O
cytosine B
arabinoside I
is O
a O
therapy O
that O
is O
potentially O
toxic O
to O
the O
peripheral O
nervous O
system O
, O
and O
auto O
/ O
alloimmunity O
may O
play O
an O
important O
role O
in O
these O
mechanisms O
. O

Dopamine B
antagonist O
fluphenazine B
, O
D O
- O
1 O
antagonist O
SCH B
23390 I
or O
D O
- O
2 O
antagonist O
sulpiride B
induced O
catalepsy O
. O

Combination O
of O
SCH B
23390 I
with O
sulpiride B
did O
not O
induce O
catalepsy O
potentiation O
. O

D O
- O
1 O
agonist O
SKF B
38393 I
or O
D O
- O
2 O
agonist O
quinpirole B
decreased O
the O
catalepsy O
induced O
by O
fluphenazine B
, O
SCH B
23390 I
or O
sulpiride B
. O

D O
- O
1 O
agonist O
SKF B
38393 I
or O
D O
- O
2 O
agonist O
quinpirole B
decreased O
the O
catalepsy O
induced O
by O
fluphenazine B
, O
SCH B
23390 I
or O
sulpiride B
. O

Combination O
of O
SKF B
38393 I
with O
quinpirole B
did O
not O
cause O
potentiated O
inhibitory O
effect O
on O
catalepsy O
induced O
by O
dopamine B
antagonists O
. O

Effects O
of O
UMB24 B
and O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
, O
putative O
sigma2 O
- O
preferring O
antagonists O
, O
on O
behavioral O
toxic O
and O
stimulant O
effects O
of O
cocaine B
in O
mice O
. O

To O
begin O
addressing O
this O
need O
, O
we O
characterized O
UMB24 B
( O
1 B
- I
( I
2 I
- I
phenethyl I
) I
- I
4 I
- I
( I
2 I
- I
pyridyl I
) I
- I
piperazine I
) O
and O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
( O
3alpha B
- I
tropanyl I
- I
2 I
- I
( I
4 I
- I
chorophenoxy I
) I
butyrate I
) O
in O
receptor O
binding O
and O
behavioral O
studies O
. O

Receptor O
binding O
studies O
confirmed O
that O
UMB24 B
and O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
display O
preferential O
affinity O
for O
sigma2 O
over O
sigma1 O
receptors O
. O

In O
behavioral O
studies O
, O
pretreatment O
of O
Swiss O
Webster O
mice O
with O
UMB24 B
or O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
significantly O
attenuated O
cocaine B
- O
induced O
convulsions O
and O
locomotor O
activity O
, O
but O
not O
lethality O
. O

When O
administered O
alone O
, O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
produced O
no O
significant O
effects O
compared O
to O
control O
injections O
of O
saline O
, O
but O
UMB24 B
had O
locomotor O
depressant O
actions O
. O

Radiolabeled B
metaiodobenzylguanidine I
( O
MIBG B
) O
, O
an O
analog O
of O
norepinephrine B
( O
NE B
) O
, O
serves O
as O
an O
index O
of O
adrenergic O
neuron O
integrity O
and O
function O
. O

Peripheral O
iron B
dextran I
induced O
degeneration O
of O
dopaminergic O
neurons O
in O
rat O
substantia O
nigra O
. O

To O
demonstrate O
the O
relationship O
between O
peripheral O
iron B
overload O
and O
dopaminergic O
neuron O
loss O
in O
rat O
substantia O
nigra O
( O
SN O
) O
, O
in O
the O
present O
study O
we O
used O
fast O
cyclic O
voltammetry O
, O
tyrosine B
hydroxylase O
( O
TH O
) O
immunohistochemistry O
, O
Perls O
' O
iron B
staining O
, O
and O
high O
performance O
liquid O
chromatography O
- O
electrochemical O
detection O
to O
study O
the O
degeneration O
of O
dopaminergic O
neurons O
and O
increased O
iron B
content O
in O
the O
SN O
of O
iron B
dextran I
overloaded O
animals O
. O

The O
findings O
showed O
that O
peripheral O
iron B
dextran I
overload O
increased O
the O
iron B
staining O
positive O
cells O
and O
reduced O
the O
number O
of O
TH O
- O
immunoreactive O
neurons O
in O
the O
SN O
. O

These O
results O
suggest O
that O
peripheral O
iron B
dextran I
can O
increase O
the O
iron B
level O
in O
the O
SN O
, O
where O
excessive O
iron B
causes O
the O
degeneration O
of O
dopaminergic O
neurons O
. O

Intraocular O
pressure O
in O
patients O
with O
uveitis O
treated O
with O
fluocinolone B
acetonide I
implants O
. O

OBJECTIVE O
: O
To O
report O
the O
incidence O
and O
management O
of O
elevated O
intraocular O
pressure O
( O
IOP O
) O
in O
patients O
with O
uveitis O
treated O
with O
the O
fluocinolone B
acetonide I
( O
FA B
) O
intravitreal O
implant O
. O

Gastrointestinal O
tolerability O
of O
etoricoxib B
in O
rheumatoid O
arthritis O
patients O
: O
results O
of O
the O
etoricoxib B
vs O
diclofenac B
sodium I
gastrointestinal O
tolerability O
and O
effectiveness O
trial O
( O
EDGE O
- O
II O
) O
. O

Myocardial O
infarction O
in O
pregnancy O
associated O
with O
clomiphene B
citrate I
for O
ovulation O
induction O
: O
a O
case O
report O
. O

BACKGROUND O
: O
Clomiphene B
citrate I
( O
CC B
) O
is O
commonly O
prescribed O
for O
ovulation O
induction O
. O

Protective O
effects O
of O
antithrombin O
on O
puromycin B
aminonucleoside I
nephrosis O
in O
rats O
. O

We O
investigated O
the O
effects O
of O
antithrombin O
, O
a O
plasma O
inhibitor O
of O
coagulation O
factors O
, O
in O
rats O
with O
puromycin B
aminonucleoside I
- O
induced O
nephrosis O
, O
which O
is O
an O
experimental O
model O
of O
human O
nephrotic O
syndrome O
. O

Antithrombin O
( O
50 O
or O
500 O
IU O
/ O
kg O
/ O
i O
. O
v O
. O
) O
was O
administered O
to O
rats O
once O
a O
day O
for O
10 O
days O
immediately O
after O
the O
injection O
of O
puromycin B
aminonucleoside I
( O
50 O
mg O
/ O
kg O
/ O
i O
. O
v O
. O
) O
. O

Treatment O
with O
antithrombin O
attenuated O
the O
puromycin B
aminonucleoside I
- O
induced O
hematological O
abnormalities O
. O

Puromycin B
aminonucleoside I
- O
induced O
renal O
dysfunction O
and O
hyperlipidemia O
were O
also O
suppressed O
. O

In O
addition O
, O
antithrombin O
treatment O
markedly O
suppressed O
puromycin B
aminonucleoside I
- O
induced O
apoptosis O
of O
renal O
tubular O
epithelial O
cells O
. O

Furthermore O
, O
puromycin B
aminonucleoside I
- O
induced O
increases O
in O
renal O
cytokine O
content O
were O
also O
decreased O
. O

These O
findings O
suggest O
that O
thrombin O
plays O
an O
important O
role O
in O
the O
pathogenesis O
of O
puromycin B
aminonucleoside I
- O
induced O
nephrotic O
syndrome O
. O

Etiologic O
factors O
in O
the O
pathogenesis O
of O
liver O
tumors O
associated O
with O
oral B
contraceptives I
. O

Within O
the O
last O
several O
years O
, O
previously O
rare O
liver O
tumors O
have O
been O
seen O
in O
young O
women O
using O
oral B
contraceptive I
steroids B
. O

The O
Registry O
for O
Liver O
Tumors O
Associated O
with O
Oral B
Contraceptives I
at O
the O
University O
of O
California O
, O
Irvine O
, O
has O
clearly O
identified O
27 O
cases O
. O

Significant O
statistical O
etiologic O
factors O
include O
prolonged O
uninterrupted O
usage O
of O
oral B
contraceptive I
steroids B
. O

Effect O
of O
increasing O
intraperitoneal O
infusion O
rates O
on O
bupropion B
hydrochloride I
- O
induced O
seizures O
in O
mice O
. O

METHODS O
: O
We O
investigated O
the O
effect O
of O
varying O
the O
intraperitoneal O
infusion O
rates O
of O
bupropion B
HCl I
120 O
mg O
/ O
kg O
, O
a O
known O
convulsive O
dose O
50 O
( O
CD50 O
) O
, O
on O
the O
incidence O
and O
severity O
of O
bupropion B
- O
induced O
convulsions O
in O
the O
Swiss O
albino O
mice O
. O

A O
total O
of O
69 O
mice O
, O
approximately O
7 O
weeks O
of O
age O
, O
and O
weighing O
21 O
. O
0 O
to O
29 O
. O
1 O
g O
were O
randomly O
assigned O
to O
bupropion B
HCl I
120 O
mg O
/ O
kg O
treatment O
by O
intraperitoneal O
( O
IP O
) O
administration O
in O
7 O
groups O
( O
9 O
to O
10 O
animals O
per O
group O
) O
. O

Bupropion B
HCl I
was O
infused O
through O
a O
surgically O
implanted O
IP O
dosing O
catheter O
with O
infusions O
in O
each O
group O
of O
0 O
min O
, O
15 O
min O
, O
30 O
min O
, O
60 O
min O
, O
90 O
min O
, O
120 O
min O
, O
and O
240 O
min O
. O

RESULTS O
: O
The O
results O
showed O
that O
IP O
administration O
of O
bupropion B
HCl I
120 O
mg O
/ O
kg O
by O
bolus O
injection O
induced O
convulsions O
in O
6 O
out O
of O
10 O
mice O
( O
60 O
% O
of O
convulsing O
mice O
) O
in O
group O
1 O
. O

Logistic O
regression O
analysis O
revealed O
that O
infusion O
time O
was O
significant O
( O
p O
= O
0 O
. O
0004 O
; O
odds O
ratio O
= O
0 O
. O
974 O
) O
and O
increasing O
the O
IP O
infusion O
time O
of O
bupropion B
HCl I
120 O
mg O
/ O
kg O
was O
associated O
with O
a O
91 O
% O
reduced O
odds O
of O
convulsions O
at O
infusion O
times O
of O
15 O
to O
90 O
min O
compared O
to O
bolus O
injection O
. O

Identification O
of O
a O
simple O
and O
sensitive O
microplate O
method O
for O
the O
detection O
of O
oversulfated O
chondroitin B
sulfate I
in O
heparin B
products O
. O

Recently O
, O
a O
number O
of O
commercial O
lots O
of O
heparin B
products O
were O
found O
to O
be O
contaminated O
with O
an O
oversulfated O
chondroitin B
sulfate I
( O
OSCS O
) O
derivative O
that O
could O
elicit O
a O
hypotensive O
response O
in O
pigs O
following O
a O
single O
high O
- O
dose O
infusion O
. O

5 B
flourouracil I
- O
induced O
apical O
ballooning O
syndrome O
: O
a O
case O
report O
. O

The O
present O
study O
was O
undertaken O
to O
assess O
lithium B
- O
induced O
polyuria O
in O
mice O
deficient O
in O
microsomal O
prostaglandin B
E I
synthase O
- O
1 O
( O
mPGES O
- O
1 O
) O
. O

Fenoldopam B
mesylate I
is O
a O
specific O
DA1 O
receptor O
agonist O
that O
lowers O
blood O
pressure O
by O
vasodilatation O
. O

Acute O
analgesic O
and O
antiinflammatory O
activities O
were O
ascertained O
using O
acetic B
acid I
induced O
writhing O
model O
( O
mice O
) O
and O
carrageenan B
- O
induced O
rat O
paw O
edema O
model O
, O
respectively O
. O

The O
beneficial O
effects O
of O
vitamin B
C I
administration O
to O
gentamicin B
- O
treated O
animals O
are O
also O
confirmed O
through O
: O
lower O
level O
of O
blood O
urea B
and O
creatinine B
and O
higher O
level O
of O
potassium B
. O

Vitamin B
C I
administration O
induced O
slowdown O
of O
pressure O
change O
back O
to O
the O
control O
values O
. O

The O
pressure O
dynamic O
properties O
, O
quantitatively O
defined O
by O
comparative O
pressure O
dynamic O
and O
total O
pressure O
dynamic O
, O
confirm O
the O
alteration O
in O
dynamic O
response O
of O
blood O
vessels O
during O
the O
change O
of O
pressure O
in O
gentamicin B
- O
treated O
animals O
and O
beneficial O
effects O
of O
vitamin B
C I
administration O
. O

High O
- O
dose O
tranexamic B
Acid I
is O
associated O
with O
nonischemic O
clinical O
seizures O
in O
cardiac O
surgical O
patients O
. O

These O
events O
were O
temporally O
coincident O
with O
the O
initial O
use O
of O
high O
- O
dose O
tranexamic B
acid I
( O
TXA B
) O
therapy O
after O
withdrawal O
of O
aprotinin O
from O
general O
clinical O
usage O
. O

Risk O
of O
nephropathy O
after O
consumption O
of O
nonionic O
contrast B
media I
by O
children O
undergoing O
cardiac O
angiography O
: O
a O
prospective O
study O
. O

Despite O
increasing O
reports O
on O
nonionic O
contrast B
media I
- O
induced O
nephropathy O
( O
CIN O
) O
in O
hospitalized O
adult O
patients O
during O
cardiac O
procedures O
, O
the O
studies O
in O
pediatrics O
are O
limited O
, O
with O
even O
less O
focus O
on O
possible O
predisposing O
factors O
and O
preventive O
measures O
for O
patients O
undergoing O
cardiac O
angiography O
. O

This O
prospective O
study O
determined O
the O
incidence O
of O
CIN O
for O
two O
nonionic O
contrast B
media I
( O
CM B
) O
, O
iopromide B
and O
iohexol B
, O
among O
80 O
patients O
younger O
than O
18 O
years O
and O
compared O
the O
rates O
for O
this O
complication O
in O
relation O
to O
the O
type O
and O
dosage O
of O
CM B
and O
the O
presence O
of O
cyanosis O
. O

Anesthesia O
was O
maintained O
with O
fentanyl B
, O
nitrous B
oxide I
, O
oxygen B
, O
and O
isoflurane B
. O

Coenzyme B
Q10 I
treatment O
ameliorates O
acute O
cisplatin B
nephrotoxicity O
in O
mice O
. O

The O
nephroprotective O
effect O
of O
coenzyme B
Q10 I
was O
investigated O
in O
mice O
with O
acute O
renal O
injury O
induced O
by O
a O
single O
i O
. O
p O
. O
injection O
of O
cisplatin B
( O
5 O
mg O
/ O
kg O
) O
. O

Coenzyme B
Q10 I
treatment O
( O
10 O
mg O
/ O
kg O
/ O
day O
, O
i O
. O
p O
. O
) O
was O
applied O
for O
6 O
consecutive O
days O
, O
starting O
1 O
day O
before O
cisplatin B
administration O
. O

Coenzyme B
Q10 I
significantly O
reduced O
blood B
urea I
nitrogen I
and O
serum O
creatinine B
levels O
which O
were O
increased O
by O
cisplatin B
. O

Coenzyme B
Q10 I
significantly O
compensated O
deficits O
in O
the O
antioxidant O
defense O
mechanisms O
( O
reduced B
glutathione I
level O
and O
superoxide B
dismutase O
activity O
) O
, O
suppressed O
lipid O
peroxidation O
, O
decreased O
the O
elevations O
of O
tumor O
necrosis O
factor O
- O
alpha O
, O
nitric B
oxide I
and O
platinum B
ion O
concentration O
, O
and O
attenuated O
the O
reductions O
of O
selenium B
and O
zinc B
ions O
in O
renal O
tissue O
resulted O
from O
cisplatin B
administration O
. O

Coenzyme B
Q10 I
significantly O
compensated O
deficits O
in O
the O
antioxidant O
defense O
mechanisms O
( O
reduced B
glutathione I
level O
and O
superoxide B
dismutase O
activity O
) O
, O
suppressed O
lipid O
peroxidation O
, O
decreased O
the O
elevations O
of O
tumor O
necrosis O
factor O
- O
alpha O
, O
nitric B
oxide I
and O
platinum B
ion O
concentration O
, O
and O
attenuated O
the O
reductions O
of O
selenium B
and O
zinc B
ions O
in O
renal O
tissue O
resulted O
from O
cisplatin B
administration O
. O

Coenzyme B
Q10 I
significantly O
compensated O
deficits O
in O
the O
antioxidant O
defense O
mechanisms O
( O
reduced B
glutathione I
level O
and O
superoxide B
dismutase O
activity O
) O
, O
suppressed O
lipid O
peroxidation O
, O
decreased O
the O
elevations O
of O
tumor O
necrosis O
factor O
- O
alpha O
, O
nitric B
oxide I
and O
platinum B
ion O
concentration O
, O
and O
attenuated O
the O
reductions O
of O
selenium B
and O
zinc B
ions O
in O
renal O
tissue O
resulted O
from O
cisplatin B
administration O
. O

Also O
, O
histopathological O
renal O
tissue O
damage O
mediated O
by O
cisplatin B
was O
ameliorated O
by O
coenzyme B
Q10 I
treatment O
. O

Immunohistochemical O
analysis O
revealed O
that O
coenzyme B
Q10 I
significantly O
decreased O
the O
cisplatin B
- O
induced O
overexpression O
of O
inducible O
nitric B
oxide I
synthase O
, O
nuclear O
factor O
- O
kappaB O
, O
caspase O
- O
3 O
and O
p53 O
in O
renal O
tissue O
. O

Immunohistochemical O
analysis O
revealed O
that O
coenzyme B
Q10 I
significantly O
decreased O
the O
cisplatin B
- O
induced O
overexpression O
of O
inducible O
nitric B
oxide I
synthase O
, O
nuclear O
factor O
- O
kappaB O
, O
caspase O
- O
3 O
and O
p53 O
in O
renal O
tissue O
. O

It O
was O
concluded O
that O
coenzyme B
Q10 I
represents O
a O
potential O
therapeutic O
option O
to O
protect O
against O
acute O
cisplatin B
nephrotoxicity O
commonly O
encountered O
in O
clinical O
practice O
. O

Functional O
evidence O
relating O
the O
IC O
to O
motor O
behavior O
derives O
from O
experiments O
showing O
that O
activation O
of O
the O
IC O
by O
electrical O
stimulation O
or O
excitatory O
amino B
acid I
microinjection O
causes O
freezing O
, O
escape O
- O
like O
behavior O
, O
and O
immobility O
. O

The O
present O
study O
examined O
the O
influence O
of O
excitatory O
amino B
acid I
- O
mediated O
mechanisms O
in O
the O
IC O
on O
the O
catalepsy O
induced O
by O
the O
dopamine B
receptor O
blocker O
haloperidol B
administered O
systemically O
( O
1 O
or O
0 O
. O
5 O
mg O
/ O
kg O
) O
in O
rats O
. O

In O
group O
- O
1 O
( O
n O
= O
10 O
) O
hippocampal O
DBS O
was O
off O
and O
in O
the O
group O
- O
2 O
( O
n O
= O
10 O
) O
hippocampal O
DBS O
was O
on O
( O
185 O
Hz O
, O
0 O
. O
5V O
, O
1V O
, O
2V O
, O
and O
5V O
for O
60 O
sec O
) O
following O
penicillin B
G I
injection O
intracortically O
. O

Central O
vein O
thrombosis O
and O
topical O
dipivalyl B
epinephrine I
. O

A O
report O
is O
given O
on O
an O
83 O
- O
year O
- O
old O
female O
who O
acquired O
central O
vein O
thrombosis O
in O
her O
seeing O
eye O
one O
day O
after O
having O
started O
topical O
medication O
with O
dipivalyl B
epinephrine I
for O
advanced O
glaucoma O
discovered O
in O
the O
other O
eye O
. O

The O
effects O
of O
intrathecal O
administration O
of O
prostaglandins B
on O
pain O
responses O
in O
conscious O
mice O
were O
evaluated O
by O
using O
hot O
plate O
and O
acetic B
acid I
writhing O
tests O
. O

Prostaglandin B
D2 I
( O
0 O
. O
5 O
- O
3 O
ng O
/ O
mouse O
) O
had O
a O
hyperalgesic O
action O
on O
the O
response O
to O
a O
hot O
plate O
during O
a O
3 O
- O
60 O
min O
period O
after O
injection O
. O

Prostaglandin B
E2 I
showed O
a O
hyperalgesic O
effect O
at O
doses O
of O
1 O
pg B
to O
10 O
ng O
/ O
mouse O
, O
but O
the O
effect O
lasted O
shorter O
( O
3 O
- O
30 O
min O
) O
than O
that O
of O
prostaglandin B
D2 I
. O

Prostaglandin B
E2 I
showed O
a O
hyperalgesic O
effect O
at O
doses O
of O
1 O
pg B
to O
10 O
ng O
/ O
mouse O
, O
but O
the O
effect O
lasted O
shorter O
( O
3 O
- O
30 O
min O
) O
than O
that O
of O
prostaglandin B
D2 I
. O

Similar O
results O
were O
obtained O
by O
acetic B
acid I
writhing O
tests O
. O

The O
hyperalgesic O
effect O
of O
prostaglandin B
D2 I
was O
blocked O
by O
simultaneous O
injection O
of O
a O
substance O
P O
antagonist O
( O
greater O
than O
or O
equal O
to O
100 O
ng O
) O
but O
not O
by O
AH6809 B
, O
a O
prostanoid O
EP1 O
- O
receptor O
antagonist O
. O

Conversely O
, O
prostaglandin B
E2 I
- O
induced O
hyperalgesia O
was O
blocked O
by O
AH6809 B
( O
greater O
than O
or O
equal O
to O
500 O
ng O
) O
but O
not O
by O
the O
substance O
P O
antagonist O
. O

These O
results O
demonstrate O
that O
both O
prostaglandin B
D2 I
and O
prostaglandin B
E2 I
exert O
hyperalgesia O
in O
the O
spinal O
cord O
, O
but O
in O
different O
ways O
. O

These O
results O
demonstrate O
that O
both O
prostaglandin B
D2 I
and O
prostaglandin B
E2 I
exert O
hyperalgesia O
in O
the O
spinal O
cord O
, O
but O
in O
different O
ways O
. O

Protective O
effect O
of O
a O
specific O
platelet O
- O
activating O
factor O
antagonist O
, O
BN B
52021 I
, O
on O
bupivacaine B
- O
induced O
cardiovascular O
impairments O
in O
rats O
. O

Intravenous O
injection O
of O
the O
specific O
platelet O
- O
activating O
factor O
( O
PAF O
) O
antagonist O
BN B
52021 I
( O
10 O
mg O
/ O
kg O
) O
, O
30 O
min O
before O
bupivacaine B
administration O
( O
2 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
suppressed O
both O
the O
decrease O
of O
MBP O
and O
HR O
. O

In O
contrast O
, O
doses O
of O
1 O
mg O
/ O
kg O
BN B
52021 I
given O
30 O
min O
before O
or O
10 O
mg O
/ O
kg O
administered O
5 O
min O
before O
i O
. O
v O
. O
injection O
of O
bupivacaine B
were O
ineffective O
. O

When O
BN B
52021 I
( O
20 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
was O
injected O
immediately O
after O
bupivacaine B
( O
2 O
mg O
/ O
kg O
) O
, O
a O
partial O
reversion O
of O
the O
decrease O
of O
MBP O
and O
HR O
was O
observed O
, O
whereas O
the O
dose O
of O
10 O
mg O
/ O
kg O
was O
ineffective O
. O

A O
partial O
recovery O
of O
bupivacaine B
- O
induced O
ECG O
alterations O
was O
observed O
after O
pretreatment O
of O
the O
rats O
with O
BN B
52021 I
. O

Since O
the O
administration O
of O
BN B
52021 I
, O
at O
all O
doses O
studied O
, O
did O
not O
alter O
MBP O
and O
HR O
at O
the O
doses O
used O
, O
the O
bulk O
of O
these O
results O
clearly O
demonstrate O
a O
protective O
action O
of O
BN B
52021 I
, O
a O
specific O
antagonist O
of O
PAF O
, O
against O
bupivacaine B
- O
induced O
cardiovascular O
toxicity O
. O

Since O
the O
administration O
of O
BN B
52021 I
, O
at O
all O
doses O
studied O
, O
did O
not O
alter O
MBP O
and O
HR O
at O
the O
doses O
used O
, O
the O
bulk O
of O
these O
results O
clearly O
demonstrate O
a O
protective O
action O
of O
BN B
52021 I
, O
a O
specific O
antagonist O
of O
PAF O
, O
against O
bupivacaine B
- O
induced O
cardiovascular O
toxicity O
. O

These O
findings O
are O
consistent O
with O
the O
postulated O
mechanism O
for O
this O
unusual O
syndrome O
: O
acute O
diffuse O
crystallization O
of O
uric B
acid I
in O
renal O
tubules O
. O

Neuromuscular O
blockade O
with O
magnesium B
sulfate I
and O
nifedipine B
. O

A O
patient O
who O
received O
tocolysis O
with O
nifedipine B
developed O
neuromuscular O
blockade O
after O
500 O
mg O
of O
magnesium B
sulfate I
was O
administered O
. O

The O
only O
known O
risk O
factor O
was O
" O
low O
- O
dose O
" O
oral B
contraceptive I
pills O
. O

50 O
mg O
/ O
kg O
, O
i O
. O
v O
. O
thiopental B
produced O
respiratory O
arrest O
with O
further O
increase O
in O
GABA B
and O
decrease O
in O
glutamate B
again O
in O
cortex O
and O
brain O
stem O
without O
affecting O
any O
of O
the O
amino B
acids I
studied O
in O
four O
regions O
of O
rat O
brain O
. O

Azelastine B
, O
a O
novel O
antiallergic O
medication O
, O
was O
compared O
with O
chlorpheniramine B
maleate I
and O
placebo O
for O
efficacy O
and O
safety O
in O
the O
treatment O
of O
spring O
allergic O
rhinitis O
in O
a O
multicenter O
, O
double O
- O
blind O
, O
multiple O
- O
dose O
, O
parallel O
- O
groups O
study O
. O

Mitomycin B
C I
associated O
hemolytic O
uremic O
syndrome O
. O

Mitomycin B
C I
associated O
Hemolytic O
Uremic O
Syndrome O
( O
HUS O
) O
is O
a O
potentially O
fatal O
but O
uncommon O
condition O
that O
is O
not O
yet O
widely O
recognised O
. O

It O
consists O
of O
microangiopathic O
hemolytic O
anemia O
, O
thrombocytopenia O
and O
progressive O
renal O
failure O
associated O
with O
mitomycin B
C I
treatment O
and O
affects O
about O
10 O
% O
of O
patients O
treated O
with O
this O
agent O
. O

The O
renal O
failure O
usually O
develops O
about O
8 O
- O
10 O
mth O
after O
start O
of O
mitomycin B
C I
treatment O
and O
the O
mortality O
is O
approximately O
60 O
% O
from O
renal O
failure O
or O
pulmonary O
edema O
. O

The O
mechanism O
of O
action O
is O
postulated O
as O
mitomycin B
C I
- O
induced O
endothelial O
cell O
damage O
. O

We O
describe O
the O
clinical O
course O
and O
pathological O
findings O
in O
a O
65 O
yr O
- O
old O
man O
with O
gastric O
adenocarcinoma O
who O
developed O
renal O
failure O
and O
thrombocytopenia O
while O
on O
treatment O
with O
mitomycin B
C I
and O
died O
in O
pulmonary O
edema O
. O

Chorea O
associated O
with O
oral B
contraception I
. O

Three O
patients O
developed O
chorea O
while O
receiving O
oral B
contraceptives I
. O

The O
third O
patient O
had O
acute O
amphetamine B
- O
induced O
chorea O
after O
prolonged O
oral B
contraception I
. O

Co O
- O
carcinogenic O
effect O
of O
retinyl B
acetate I
on O
forestomach O
carcinogenesis O
of O
male O
F344 O
rats O
induced O
with O
butylated B
hydroxyanisole I
. O

Co O
- O
carcinogenic O
effect O
of O
retinyl B
acetate I
on O
forestomach O
carcinogenesis O
of O
male O
F344 O
rats O
induced O
with O
butylated B
hydroxyanisole I
. O

The O
potential O
modifying O
effect O
of O
retinyl B
acetate I
( O
RA B
) O
on O
butylated B
hydroxyanisole I
( O
BHA B
) O
- O
induced O
rat O
forestomach O
tumorigenesis O
was O
examined O
. O

The O
potential O
modifying O
effect O
of O
retinyl B
acetate I
( O
RA B
) O
on O
butylated B
hydroxyanisole I
( O
BHA B
) O
- O
induced O
rat O
forestomach O
tumorigenesis O
was O
examined O
. O

A O
prospective O
study O
on O
the O
dose O
dependency O
of O
cardiotoxicity O
induced O
by O
mitomycin B
C I
. O

Since O
1975 O
mitomycin B
C I
( O
MMC B
) O
has O
been O
suggested O
to O
be O
cardiotoxic O
, O
especially O
when O
combined O
with O
or O
given O
following O
doxorubicin B
. O

Group O
II O
showed O
a O
better O
perioperative O
renal O
function O
as O
determined O
by O
serum O
blood O
urea B
nitrogen I
and O
serum O
creatinine B
levels O
. O

In O
a O
12 O
- O
week O
controlled O
study O
ethopropazine B
was O
compared O
to O
benztropine B
in O
the O
treatment O
of O
parkinsonism O
induced O
by O
fluphenazine B
enanthate I
in O
60 O
schizophrenic O
outpatients O
. O

Quinidine B
phenylethylbarbiturate I
- O
induced O
fulminant O
hepatitis O
in O
a O
pregnant O
woman O
. O

We O
report O
the O
case O
of O
a O
19 O
- O
year O
- O
old O
Laotian O
patient O
affected O
by O
fulminant O
hepatitis O
during O
the O
third O
trimester O
of O
her O
pregnancy O
after O
a O
1 O
- O
month O
administration O
of O
quinidine B
phenylethylbarbiturate I
. O

Recent O
preclinical O
and O
clinical O
studies O
with O
the O
thymidylate O
synthase O
inhibitor O
N10 B
- I
propargyl I
- I
5 I
, I
8 I
- I
dideazafolic I
acid I
( O
CB B
3717 I
) O
. O

CB B
3717 I
, O
N10 B
- I
propargyl I
- I
5 I
, I
8 I
- I
dideazafolic I
acid I
, O
is O
a O
tight O
- O
binding O
inhibitor O
of O
thymidylate O
synthase O
( O
TS O
) O
whose O
cytotoxicity O
is O
mediated O
solely O
through O
the O
inhibition O
of O
this O
enzyme O
. O

Recent O
preclinical O
studies O
have O
focused O
on O
the O
intracellular O
formation O
of O
CB B
3717 I
polyglutamates O
. O

Following O
a O
12 O
- O
hour O
exposure O
of O
L1210 O
cells O
to O
50 O
microM O
[ O
3H O
] O
CB B
3717 I
, O
30 O
% O
of O
the O
extractable O
radioactivity O
could O
be O
accounted O
for O
as O
CB B
3717 I
tetra O
- O
and O
pentaglutamate O
, O
as O
determined O
by O
high O
- O
pressure O
liquid O
chromatography O
( O
HPLC O
) O
analyses O
. O

Following O
a O
12 O
- O
hour O
exposure O
of O
L1210 O
cells O
to O
50 O
microM O
[ O
3H O
] O
CB B
3717 I
, O
30 O
% O
of O
the O
extractable O
radioactivity O
could O
be O
accounted O
for O
as O
CB B
3717 I
tetra O
- O
and O
pentaglutamate O
, O
as O
determined O
by O
high O
- O
pressure O
liquid O
chromatography O
( O
HPLC O
) O
analyses O
. O

As O
inhibitors O
of O
isolated O
L1210 O
TS O
, O
CB O
3717 O
di O
- O
, O
tri O
- O
, O
tetra O
- O
and O
pentaglutamate O
are O
26 O
- O
, O
87 O
- O
, O
119 O
- O
and O
114 O
- O
fold O
more O
potent O
than O
CB B
3717 I
, O
respectively O
, O
and O
their O
formation O
may O
, O
therefore O
, O
be O
an O
important O
determinant O
of O
CB B
3717 I
cytotoxicity O
. O

As O
inhibitors O
of O
isolated O
L1210 O
TS O
, O
CB O
3717 O
di O
- O
, O
tri O
- O
, O
tetra O
- O
and O
pentaglutamate O
are O
26 O
- O
, O
87 O
- O
, O
119 O
- O
and O
114 O
- O
fold O
more O
potent O
than O
CB B
3717 I
, O
respectively O
, O
and O
their O
formation O
may O
, O
therefore O
, O
be O
an O
important O
determinant O
of O
CB B
3717 I
cytotoxicity O
. O

In O
early O
clinical O
studies O
with O
CB B
3717 I
, O
activity O
has O
been O
seen O
in O
breast O
cancer O
, O
ovarian O
cancer O
, O
hepatoma O
, O
and O
mesothelioma O
. O

This O
latter O
effect O
is O
thought O
to O
be O
due O
to O
drug O
precipitation O
within O
the O
renal O
tubule O
as O
a O
result O
of O
the O
poor O
solubility O
of O
CB B
3717 I
under O
acidic O
conditions O
. O

In O
an O
attempt O
to O
overcome O
this O
problem O
, O
a O
clinical O
trial O
of O
CB B
3717 I
administered O
with O
alkaline O
diuresis O
is O
under O
way O
. O

Pharmacokinetic O
investigations O
have O
shown O
that O
alkaline O
diuresis O
does O
not O
alter O
CB B
3717 I
plasma O
levels O
or O
urinary O
excretion O
and O
that O
satisfactory O
urinary O
alkalinization O
can O
be O
readily O
achieved O
. O

More O
than O
50 O
% O
of O
Lobund O
- O
Wistar O
( O
L O
- O
W O
) O
strain O
rats O
developed O
large O
, O
palpable O
prostate O
adenocarcinomas O
( O
PAs O
) O
following O
treatments O
with O
N B
- I
nitroso I
- I
N I
- I
methylurea I
( O
CAS O
: O
684 O
- O
93 O
- O
5 O
) O
and O
testosterone B
propionate I
[ O
( O
TP B
) O
CAS O
: O
57 O
- O
85 O
- O
2 O
] O
, O
and O
most O
of O
the O
tumor O
- O
bearing O
rats O
manifested O
metastatic O
lesions O
. O

We O
prospectively O
compared O
the O
efficacy O
and O
safety O
of O
netilmicin B
sulfate I
or O
tobramycin B
sulfate I
in O
conjunction O
with O
piperacillin B
sodium I
in O
118 O
immunocompromised O
patients O
with O
presumed O
severe O
infections O
. O

We O
prospectively O
compared O
the O
efficacy O
and O
safety O
of O
netilmicin B
sulfate I
or O
tobramycin B
sulfate I
in O
conjunction O
with O
piperacillin B
sodium I
in O
118 O
immunocompromised O
patients O
with O
presumed O
severe O
infections O
. O

We O
prospectively O
compared O
the O
efficacy O
and O
safety O
of O
netilmicin B
sulfate I
or O
tobramycin B
sulfate I
in O
conjunction O
with O
piperacillin B
sodium I
in O
118 O
immunocompromised O
patients O
with O
presumed O
severe O
infections O
. O

Acute O
experimental O
models O
of O
renal O
damage O
to O
the O
proximal O
tubular O
, O
glomerular O
, O
and O
papillary O
regions O
of O
the O
rat O
were O
produced O
by O
administration O
of O
hexachloro B
- I
1 I
: I
3 I
- I
butadiene I
( O
HCBD B
) O
, O
puromycin B
aminonucleoside I
( O
PAN B
) O
, O
and O
2 B
- I
bromoethylamine I
( O
BEA B
) O
, O
respectively O
. O

The O
combined O
administration O
of O
CSA B
and O
various O
chemotherapeutic O
drugs O
with O
a O
nephrotoxic O
potential O
, O
such O
as O
gentamicin B
( O
at O
therapeutic O
doses O
) O
, O
amphothericin B
B I
and O
ketoconazole B
, O
which O
are O
frequently O
used O
in O
immunosuppressed O
patients O
, O
did O
not O
aggravate O
the O
CSA B
induced O
toxicity O
in O
the O
rat O
model O
. O

We O
studied O
a O
thiamine B
- O
dependent O
enzyme O
, O
transketolase O
, O
from O
fibroblasts O
of O
a O
diabetic O
patient O
who O
developed O
Wernicke O
' O
s O
encephalopathy O
when O
treated O
with O
tolazamide B
, O
in O
order O
to O
delineate O
if O
this O
patient O
also O
had O
transketolase O
abnormality O
[ O
high O
Km O
for O
thiamine B
pyrophosphate I
( O
TPP B
) O
] O
, O
as O
previously O
reported O
in O
postalcoholic O
Wernicke O
- O
Korsakoff O
syndrome O
. O

Bradycardia O
due O
to O
trihexyphenidyl B
hydrochloride I
. O

A O
chronic O
schizophrenic O
patient O
was O
treated O
with O
an O
anticholinergic O
drug O
, O
trihexyphenidyl B
hydrochloride I
. O

Time O
course O
alterations O
of O
QTC O
interval O
due O
to O
hypaque B
76 I
. O

Sequential O
measurement O
of O
QT O
interval O
during O
left O
ventricular O
angiography O
was O
made O
30 O
seconds O
and O
one O
, O
three O
, O
five O
and O
ten O
minutes O
after O
injection O
of O
hypaque B
76 I
. O

Local O
anesthetics O
that O
are O
commonly O
used O
in O
ophthalmic O
surgery O
( O
0 O
. O
75 O
% O
bupivacaine B
hydrochloride I
, O
2 O
. O
0 O
% O
mepivacaine B
hydrochloride I
, O
and O
2 O
. O
0 O
% O
lidocaine B
hydrochloride I
plus O
1 O
: O
100 O
, O
000 O
epinephrine B
) O
were O
injected O
into O
the O
retrobulbar O
area O
of O
rat O
eyes O
. O

Local O
anesthetics O
that O
are O
commonly O
used O
in O
ophthalmic O
surgery O
( O
0 O
. O
75 O
% O
bupivacaine B
hydrochloride I
, O
2 O
. O
0 O
% O
mepivacaine B
hydrochloride I
, O
and O
2 O
. O
0 O
% O
lidocaine B
hydrochloride I
plus O
1 O
: O
100 O
, O
000 O
epinephrine B
) O
were O
injected O
into O
the O
retrobulbar O
area O
of O
rat O
eyes O
. O

Local O
anesthetics O
that O
are O
commonly O
used O
in O
ophthalmic O
surgery O
( O
0 O
. O
75 O
% O
bupivacaine B
hydrochloride I
, O
2 O
. O
0 O
% O
mepivacaine B
hydrochloride I
, O
and O
2 O
. O
0 O
% O
lidocaine B
hydrochloride I
plus O
1 O
: O
100 O
, O
000 O
epinephrine B
) O
were O
injected O
into O
the O
retrobulbar O
area O
of O
rat O
eyes O
. O

Numerous O
periodic B
acid I
Schiff O
( O
PAS O
) O
positive O
, O
diastase O
resistant O
cytoplasmic O
inclusion O
bodies O
which O
appeared O
as O
myelin O
figures O
in O
cytosegresomes O
under O
the O
electron O
microscope O
were O
identified O
in O
the O
proximal O
convoluted O
tubules O
. O

Long O
- O
term O
administration O
of O
quinidine B
was O
associated O
with O
persistent O
elevation O
of O
serum O
concentrations O
of O
SGOT O
, O
lactic B
acid I
dehydrogenase O
, O
and O
alkaline O
phosphatase O
. O

A O
challenge O
dose O
of O
quinidine B
caused O
clinical O
symptoms O
and O
abrupt O
elevation O
of O
SGOT O
, O
alkaline O
phosphatase O
, O
and O
lactic B
acid I
dehydrogenase O
values O
. O

Appropriate O
treatment O
consists O
of O
discontinuation O
of O
heparin B
, O
and O
anticoagulation O
with O
sodium B
warfarin I
if O
necessary O
. O

Mean O
serum O
potassium B
level O
fell O
, O
and O
urea B
and O
uric B
acid I
levels O
rose O
, O
in O
men O
and O
women O
taking O
bendrofluazide B
. O

In O
the O
propranolol B
group O
, O
serum O
potassium B
and O
uric B
acid I
levels O
rose O
in O
both O
sexes O
, O
but O
the O
urea B
level O
rose O
significantly O
in O
women O
only O
. O

One O
case O
of O
acute O
hypercalcaemia O
and O
two O
of O
recurrent O
nephrolithiasis O
are O
reported O
in O
patients O
who O
had O
regularly O
consumed O
large O
amounts O
of O
calcium B
carbon I
- I
ate I
- O
sodium B
bicarbonate I
powders O
for O
more O
than O
20 O
years O
. O

Pretreatment O
with O
ammonium B
acetate I
( O
NH4Ac B
) O
( O
6 O
mmol O
/ O
kg O
s O
. O
c O
. O
) O
approximately O
doubled O
the O
time O
morphine B
- O
treated O
mice O
remained O
on O
a O
hot O
surface O
and O
similarly O
increased O
muscular O
incoordination O
by O
diazepam B
, O
but O
NH4Ac B
treatment O
alone O
had O
no O
effect O
. O

Ibuprofen B
, O
sulindac B
, O
mefenamic B
acid I
, O
and O
low O
dose O
meclofenamic B
acid I
increased O
the O
latency O
- O
to O
- O
onset O
in O
the O
flurothyl B
and O
/ O
or O
PTZ B
models O
; O
the O
electroshock O
, O
picrotoxin B
and O
bicuculline B
models O
were O
not O
significantly O
affected O
by O
any O
of O
the O
pretreatment O
agents O
. O

Ibuprofen B
, O
sulindac B
, O
mefenamic B
acid I
, O
and O
low O
dose O
meclofenamic B
acid I
increased O
the O
latency O
- O
to O
- O
onset O
in O
the O
flurothyl B
and O
/ O
or O
PTZ B
models O
; O
the O
electroshock O
, O
picrotoxin B
and O
bicuculline B
models O
were O
not O
significantly O
affected O
by O
any O
of O
the O
pretreatment O
agents O
. O

Acute O
changes O
of O
blood O
ammonia B
may O
predict O
short O
- O
term O
adverse O
effects O
of O
valproic B
acid I
. O

Valproic B
acid I
( O
VPA B
) O
was O
given O
to O
24 O
epileptic O
patients O
who O
were O
already O
being O
treated O
with O
other O
antiepileptic O
drugs O
. O

Also O
, O
captopril B
treatment O
failed O
to O
potentiate O
or O
facilitate O
development O
of O
massive O
proteinuria O
invoked O
by O
puromycin B
aminonucleoside I
in O
SHR O
. O

Renografin B
contains O
the O
chelating O
agents O
sodium B
citrate I
and O
disodium B
edetate I
, O
while O
Hypaque B
contains O
calcium B
disodium I
edetate I
and O
no O
sodium B
citrate I
. O

Renografin B
contains O
the O
chelating O
agents O
sodium B
citrate I
and O
disodium B
edetate I
, O
while O
Hypaque B
contains O
calcium B
disodium I
edetate I
and O
no O
sodium B
citrate I
. O

Renografin B
contains O
the O
chelating O
agents O
sodium B
citrate I
and O
disodium B
edetate I
, O
while O
Hypaque B
contains O
calcium B
disodium I
edetate I
and O
no O
sodium B
citrate I
. O

A O
31 O
- O
year O
- O
old O
man O
with O
rheumatoid O
arthritis O
, O
who O
had O
previously O
been O
treated O
with O
sulindac B
, O
fenoprofen B
calcium I
, O
high O
dose O
salicylates B
and O
gold B
salts O
, O
developed O
renal O
papillary O
necrosis O
( O
RPN O
) O
4 O
months O
after O
institution O
of O
naproxen B
therapy O
. O

Tricuspid O
valve O
regurgitation O
and O
lithium B
carbonate I
toxicity O
in O
a O
newborn O
infant O
. O

Lithium B
carbonate I
may O
be O
a O
factor O
in O
the O
increasing O
incidence O
of O
congenital O
heart O
disease O
when O
taken O
during O
early O
pregnancy O
. O

Effect O
of O
calcium B
chloride I
on O
gross O
behavioural O
changes O
produced O
by O
carbachol B
and O
eserine B
in O
cats O
. O

The O
effect O
of O
calcium B
chloride I
injected O
into O
the O
cerebral O
ventricles O
of O
group O
- O
housed O
unanaesthetized O
cats O
upon O
vocalization O
( O
rage O
, O
hissing O
and O
snarling O
) O
, O
fighting O
( O
attack O
with O
paws O
and O
claws O
, O
defense O
with O
paws O
and O
claws O
and O
biting O
) O
, O
mydriasis O
, O
tremor O
and O
clonic O
- O
tonic O
convulsions O
produced O
by O
carbachol B
and O
eserine B
injected O
similarly O
was O
investigated O
. O

Calcium B
chloride I
depressed O
or O
almost O
completely O
abolished O
the O
vocalization O
and O
fighting O
due O
to O
carbachol B
and O
eserine B
. O

On O
the O
other O
hand O
, O
mydriasis O
, O
tremor O
and O
clonic O
- O
tonic O
convulsions O
evoked O
by O
carbachol B
and O
eserine B
were O
not O
significantly O
changed O
by O
calcium B
chloride I
. O

It O
is O
apparent O
that O
calcium B
chloride I
can O
" O
dissociate O
" O
vocalization O
and O
fighting O
from O
autonomic O
and O
motor O
phenomena O
such O
as O
mydriasis O
, O
tremor O
and O
clonic O
- O
tonic O
convulsions O
caused O
by O
carbachol B
and O
eserine B
. O

Calcium B
chloride I
inhibited O
the O
vocalization O
and O
fighting O
produced O
by O
carbachol B
and O
eserine B
most O
probably O
by O
a O
nonspecific O
stabilizing O
action O
on O
central O
muscarinic O
cholinoceptive O
sites O
. O

Plasma O
and O
urinary O
lipids O
and O
lipoproteins O
during O
the O
development O
of O
nephrotic O
syndrome O
induced O
in O
the O
rat O
by O
puromycin B
aminonucleoside I
. O

This O
study O
was O
undertaken O
to O
ascertain O
whether O
the O
alterations O
of O
plasma O
lipoproteins O
found O
in O
nephrotic O
syndrome O
induced O
by O
puromycin B
aminonucleoside I
were O
due O
to O
nephrotic O
syndrome O
per O
se O
, O
or O
, O
at O
least O
in O
part O
, O
to O
the O
aminonucleoside B
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
the O
changes O
in O
plasma O
and O
urinary O
lipoproteins O
during O
the O
administration O
of O
puromycin B
aminonucleoside I
( O
20 O
mg O
/ O
kg O
for O
7 O
days O
) O
and O
the O
subsequent O
development O
of O
nephrotic O
syndrome O
. O

In O
pre O
- O
nephrotic O
stage O
the O
plasma O
level O
of O
fatty B
acids I
, O
triacylglycerol B
and O
VLDL O
decreased O
while O
that O
of O
phospholipid O
, O
cholesteryl B
esters I
and O
HDL O
remained O
constant O
. O

In O
pre O
- O
nephrotic O
stage O
the O
plasma O
level O
of O
fatty B
acids I
, O
triacylglycerol B
and O
VLDL O
decreased O
while O
that O
of O
phospholipid O
, O
cholesteryl B
esters I
and O
HDL O
remained O
constant O
. O

These O
observations O
indicate O
that O
puromycin B
aminonucleoside I
alters O
plasma O
lipoproteins O
by O
lowering O
VLDL O
and O
increasing O
HDL O
. O

Nephrotoxicity O
of O
cyclosporin B
A I
and O
FK506 B
: O
inhibition O
of O
calcineurin O
phosphatase O
. O

Cyclosporin B
A I
( O
CsA B
; O
50 O
mg O
/ O
kg O
) O
and O
Fujimycine B
( O
FK506 B
; O
5 O
mg O
/ O
kg O
) O
, O
but O
not O
the O
related O
macrolide B
immunosuppressant O
rapamycin B
( O
5 O
mg O
/ O
kg O
) O
, O
caused O
a O
reduction O
of O
glomerular O
filtration O
rate O
, O
degenerative O
changes O
of O
proximal O
tubular O
epithelium O
, O
and O
hypertrophy O
of O
the O
juxtaglomerular O
apparatus O
in O
male O
Wistar O
rats O
when O
given O
for O
10 O
days O
. O

This O
coma O
was O
prevented O
with O
1 O
. O
68 O
mmol O
L B
- I
dopa I
given O
by O
gastric O
intubation O
15 O
minutes O
before O
the O
ammonium B
salt I
injection O
. O

Cholinergic O
toxicity O
resulting O
from O
ocular O
instillation O
of O
echothiophate B
iodide I
eye O
drops O
. O

A O
patient O
developed O
a O
severe O
cholinergic O
syndrome O
from O
the O
use O
of O
echothiophate B
iodide I
ophthalmic O
drops O
, O
presented O
with O
profound O
muscle O
weakness O
and O
was O
initially O
given O
the O
diagnosis O
of O
myasthenia O
gravis O
. O

Prostaglandin B
E2 I
- O
induced O
bladder O
hyperactivity O
in O
normal O
, O
conscious O
rats O
: O
involvement O
of O
tachykinins B
? O

However O
, O
shortly O
after O
the O
use O
of O
intravenous O
calcium B
chloride I
, O
the O
refractory O
hypotension O
and O
complete O
heart O
block O
resolved O
. O

The O
effects O
of O
digitalis B
glycosides I
on O
myocardial O
oxygen B
supply O
and O
demand O
are O
of O
particular O
interest O
in O
the O
presence O
of O
obstructive O
coronary O
artery O
disease O
, O
but O
have O
not O
been O
measured O
previously O
in O
man O
. O

Oral O
administration O
of O
KF17837 B
( O
2 O
. O
5 O
, O
10 O
. O
0 O
and O
30 O
. O
0 O
mg O
/ O
kg O
) O
significantly O
ameliorated O
the O
cataleptic O
responses O
induced O
by O
intracerebroventricular O
administration O
of O
an O
adenosine B
A2A O
receptor O
agonist O
, O
CGS B
21680 I
( O
10 O
micrograms O
) O
, O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
patient O
was O
treated O
with O
steroid B
pulse O
, O
plasmapheresis O
, O
cyclophosphamide B
and O
antiplatelet B
agents I
. O

Hepatic O
adenomas O
and O
focal O
nodular O
hyperplasia O
of O
the O
liver O
in O
young O
women O
on O
oral B
contraceptives I
: O
case O
reports O
. O

Two O
cases O
of O
hepatic O
adenoma O
and O
one O
of O
focal O
nodular O
hyperplasia O
presumably O
associated O
with O
the O
use O
of O
oral B
contraceptives I
, O
are O
reported O
. O

In O
situ O
hybridization O
methods O
were O
used O
to O
determine O
if O
glutamic B
acid I
decarboxylase O
( O
GAD O
) O
mRNA O
- O
containing O
neurons O
within O
the O
hilus O
of O
the O
dentate O
gyrus O
are O
vulnerable O
to O
seizure O
- O
induced O
damage O
in O
a O
model O
of O
chronic O
seizures O
. O

Additional O
neuronanatomical O
studies O
, O
including O
cresyl B
violet I
staining O
, O
neuronal O
degeneration O
methods O
, O
and O
histochemical O
localization O
of O
glial O
fibrillary O
acidic O
protein O
, O
suggested O
that O
the O
decrease O
in O
the O
number O
of O
GAD O
mRNA O
- O
containing O
neurons O
was O
related O
to O
neuronal O
loss O
rather O
than O
to O
a O
decrease O
in O
GAD O
mRNA O
levels O
. O

Pentamidine B
isethionate I
has O
been O
associated O
with O
ventricular O
tachyarrhythmias O
, O
including O
torsade O
de O
pointes O
. O

METHODS O
: O
Male O
SHR O
( O
aged O
6 O
weeks O
) O
that O
had O
been O
treated O
from O
conception O
onward O
with O
either O
captopril B
or O
vehicle O
remained O
on O
a O
basal O
sodium B
chloride I
diet O
or O
were O
fed O
a O
high O
sodium B
chloride I
diet O
. O

METHODS O
: O
Male O
SHR O
( O
aged O
6 O
weeks O
) O
that O
had O
been O
treated O
from O
conception O
onward O
with O
either O
captopril B
or O
vehicle O
remained O
on O
a O
basal O
sodium B
chloride I
diet O
or O
were O
fed O
a O
high O
sodium B
chloride I
diet O
. O

Infusion O
of O
the O
central O
nervous O
system O
alpha2 B
- I
adrenergic I
receptor I
agonist I
clonidine B
also O
resulted O
in O
a O
greater O
reduction O
in O
MAP O
in O
both O
groups O
of O
SHR O
that O
were O
fed O
the O
high O
( O
compared O
with O
the O
basal O
) O
sodium B
chloride I
diet O
. O

CONCLUSIONS O
: O
In O
both O
lifetime O
captopril B
- O
treated O
and O
control O
SHR O
, O
the O
sympathetic O
nervous O
system O
contributes O
to O
the O
pressor O
effects O
of O
a O
high O
sodium B
chloride I
diet O
. O

Increased O
sulfation O
and O
decreased O
7alpha O
- O
hydroxylation O
of O
deoxycholic B
acid I
in O
ethinyl B
estradiol I
- O
induced O
cholestasis O
in O
rats O
. O

Increased O
sulfation O
and O
decreased O
7alpha O
- O
hydroxylation O
of O
deoxycholic B
acid I
in O
ethinyl B
estradiol I
- O
induced O
cholestasis O
in O
rats O
. O

Deoxycholic B
acid I
conjugation O
, O
transport O
capacity O
, O
and O
metabolism O
were O
compared O
in O
control O
and O
ethinyl B
estradiol I
- O
treated O
rats O
. O

Deoxycholic B
acid I
conjugation O
, O
transport O
capacity O
, O
and O
metabolism O
were O
compared O
in O
control O
and O
ethinyl B
estradiol I
- O
treated O
rats O
. O

Control O
rats O
were O
found O
to O
have O
a O
lower O
capacity O
to O
transport O
deoxycholic B
acid I
than O
taurodeoxycholic B
acid I
, O
and O
both O
were O
decreased O
by O
ethinyl B
estradiol I
treatment O
. O

Control O
rats O
were O
found O
to O
have O
a O
lower O
capacity O
to O
transport O
deoxycholic B
acid I
than O
taurodeoxycholic B
acid I
, O
and O
both O
were O
decreased O
by O
ethinyl B
estradiol I
treatment O
. O

Control O
rats O
were O
found O
to O
have O
a O
lower O
capacity O
to O
transport O
deoxycholic B
acid I
than O
taurodeoxycholic B
acid I
, O
and O
both O
were O
decreased O
by O
ethinyl B
estradiol I
treatment O
. O

During O
[ O
24 O
- O
14C O
] O
sodium B
deoxycholate I
infusion O
, O
[ O
14C O
] O
biliary O
bile B
acid I
secretion O
increased O
, O
but O
bile O
flow O
did O
not O
change O
significantly O
in O
either O
control O
or O
ethinyl B
estradiol I
- O
treated O
rats O
. O

During O
[ O
24 O
- O
14C O
] O
sodium B
deoxycholate I
infusion O
, O
[ O
14C O
] O
biliary O
bile B
acid I
secretion O
increased O
, O
but O
bile O
flow O
did O
not O
change O
significantly O
in O
either O
control O
or O
ethinyl B
estradiol I
- O
treated O
rats O
. O

During O
[ O
24 O
- O
14C O
] O
sodium B
deoxycholate I
infusion O
, O
[ O
14C O
] O
biliary O
bile B
acid I
secretion O
increased O
, O
but O
bile O
flow O
did O
not O
change O
significantly O
in O
either O
control O
or O
ethinyl B
estradiol I
- O
treated O
rats O
. O

Ethinyl B
estradiol I
- O
treated O
animals O
excreted O
significantly O
less O
14C O
as O
taurocholic B
acid I
than O
did O
control O
animals O
, O
consistent O
with O
an O
impairment O
of O
7alpha O
- O
hydroxylation O
of O
taurodeoxycholic B
acid I
. O

Ethinyl B
estradiol I
- O
treated O
animals O
excreted O
significantly O
less O
14C O
as O
taurocholic B
acid I
than O
did O
control O
animals O
, O
consistent O
with O
an O
impairment O
of O
7alpha O
- O
hydroxylation O
of O
taurodeoxycholic B
acid I
. O

Ethinyl B
estradiol I
- O
treated O
animals O
excreted O
significantly O
less O
14C O
as O
taurocholic B
acid I
than O
did O
control O
animals O
, O
consistent O
with O
an O
impairment O
of O
7alpha O
- O
hydroxylation O
of O
taurodeoxycholic B
acid I
. O

Ethinyl B
estradiol I
treatment O
did O
not O
impair O
conjugation O
of O
deoxycholic B
acid I
, O
but O
did O
result O
in O
an O
increase O
in O
sulfation O
of O
taurodeoxycholic B
acid I
from O
1 O
. O
5 O
% O
in O
controls O
to O
nearly O
4 O
. O
0 O
% O
( O
P O
less O
than O
0 O
. O
01 O
) O
. O

Ethinyl B
estradiol I
treatment O
did O
not O
impair O
conjugation O
of O
deoxycholic B
acid I
, O
but O
did O
result O
in O
an O
increase O
in O
sulfation O
of O
taurodeoxycholic B
acid I
from O
1 O
. O
5 O
% O
in O
controls O
to O
nearly O
4 O
. O
0 O
% O
( O
P O
less O
than O
0 O
. O
01 O
) O
. O

Ethinyl B
estradiol I
treatment O
did O
not O
impair O
conjugation O
of O
deoxycholic B
acid I
, O
but O
did O
result O
in O
an O
increase O
in O
sulfation O
of O
taurodeoxycholic B
acid I
from O
1 O
. O
5 O
% O
in O
controls O
to O
nearly O
4 O
. O
0 O
% O
( O
P O
less O
than O
0 O
. O
01 O
) O
. O

These O
results O
are O
consistent O
with O
the O
hypothesis O
that O
the O
rat O
has O
a O
poorer O
tolerance O
for O
deoxycholic B
acid I
than O
do O
certain O
other O
species O
. O

Furthermore O
, O
the O
rat O
converts O
deoxycholic B
acid I
, O
a O
poor O
choleretic O
, O
to O
taurocholic B
acid I
, O
a O
good O
choleretic O
. O

Furthermore O
, O
the O
rat O
converts O
deoxycholic B
acid I
, O
a O
poor O
choleretic O
, O
to O
taurocholic B
acid I
, O
a O
good O
choleretic O
. O

When O
this O
conversion O
is O
impaired O
with O
ethinyl B
estradiol I
treatment O
, O
sulfation O
may O
be O
an O
important O
alternate O
pathway O
for O
excretion O
of O
this O
potentially O
harmful O
bile B
acid I
. O

When O
this O
conversion O
is O
impaired O
with O
ethinyl B
estradiol I
treatment O
, O
sulfation O
may O
be O
an O
important O
alternate O
pathway O
for O
excretion O
of O
this O
potentially O
harmful O
bile B
acid I
. O

This O
drug O
was O
initiated O
in O
association O
with O
paroxetine B
and O
dosulepine B
hydrochloride I
in O
a O
tetraparetic O
patient O
with O
chronic O
pain O
. O

Effect O
of O
calcium B
chloride I
and O
4 B
- I
aminopyridine I
therapy O
on O
desipramine B
toxicity O
in O
rats O
. O

Valsartan B
, O
a O
new O
angiotensin B
II I
antagonist O
for O
the O
treatment O
of O
essential O
hypertension O
: O
a O
comparative O
study O
of O
the O
efficacy O
and O
safety O
against O
amlodipine B
. O

OBJECTIVE O
: O
To O
compare O
the O
antihypertensive O
efficacy O
of O
a O
new O
angiotensin B
II I
antagonist O
, O
valsartan B
, O
with O
a O
reference O
therapy O
, O
amlodipine B
. O

Measures O
of O
pupillary O
oscillation O
were O
able O
to O
significantly O
distinguish O
a O
group O
of O
abstinent O
crack B
cocaine I
abusers O
endorsing O
past O
CIP O
( O
n O
= O
32 O
) O
from O
another O
group O
of O
crack B
addicts O
who O
denied O
past O
CIP O
( O
n O
= O
29 O
) O
. O

A O
phase O
I O
clinical O
study O
of O
the O
antipurine B
antifolate O
lometrexol B
( O
DDATHF B
) O
given O
with O
oral O
folic B
acid I
. O

Lometrexol B
is O
an O
antifolate O
which O
inhibits O
glycinamide B
ribonucleotide I
formyltransferase O
( O
GARFT O
) O
, O
an O
enzyme O
essential O
for O
de O
novo O
purine B
synthesis O
. O

Preclinical O
murine O
studies O
demonstrated O
that O
the O
toxicity O
of O
lometrexol B
can O
be O
prevented O
by O
low O
dose O
folic B
acid I
administration O
, O
i O
. O
e O
. O
for O
7 O
days O
prior O
to O
and O
7 O
days O
following O
a O
single O
bolus O
dose O
. O

This O
observation O
prompted O
a O
Phase O
I O
clinical O
study O
of O
lometrexol B
given O
with O
folic B
acid I
supplementation O
which O
has O
confirmed O
that O
the O
toxicity O
of O
lometrexol B
can O
be O
markedly O
reduced O
by O
folic B
acid I
supplementation O
. O

This O
observation O
prompted O
a O
Phase O
I O
clinical O
study O
of O
lometrexol B
given O
with O
folic B
acid I
supplementation O
which O
has O
confirmed O
that O
the O
toxicity O
of O
lometrexol B
can O
be O
markedly O
reduced O
by O
folic B
acid I
supplementation O
. O

Associated O
studies O
demonstrated O
that O
lometrexol B
plasma O
pharmacokinetics O
were O
not O
altered O
by O
folic B
acid I
administration O
indicating O
that O
supplementation O
is O
unlikely O
to O
reduce O
toxicity O
by O
enhancing O
lometrexol B
plasma O
clearance O
. O

Neutrophil O
superoxide B
and O
hydrogen B
peroxide I
production O
in O
patients O
with O
acute O
liver O
failure O
. O

Defects O
in O
superoxide B
and O
hydrogen B
peroxide I
production O
may O
be O
implicated O
in O
the O
high O
incidence O
of O
bacterial O
infections O
in O
patients O
with O
acute O
liver O
failure O
( O
ALF O
) O
. O

Superoxide B
and O
hydrogen B
peroxide I
production O
by O
ALF O
neutrophils O
stimulated O
with O
zymosan O
opsonized O
with O
ALF O
serum O
was O
significantly O
reduced O
compared O
with O
the O
control O
subjects O
( O
P O
< O
0 O
. O
01 O
) O
. O

Superoxide B
and O
hydrogen B
peroxide I
production O
in O
neutrophils O
stimulated O
with O
formyl B
- I
methionyl I
- I
leucyl I
- I
phenylalanine I
( O
fMLP B
) O
from O
a O
further O
18 O
ALF O
patients O
was O
unaffected O
compared O
with O
control O
neutrophils O
. O

Cholesteryl B
hemisuccinate I
treatment O
protects O
rodents O
from O
the O
toxic O
effects O
of O
acetaminophen B
, O
adriamycin B
, O
carbon B
tetrachloride I
, O
chloroform B
and O
galactosamine B
. O

Cholesteryl B
hemisuccinate I
treatment O
protects O
rodents O
from O
the O
toxic O
effects O
of O
acetaminophen B
, O
adriamycin B
, O
carbon B
tetrachloride I
, O
chloroform B
and O
galactosamine B
. O

In O
addition O
to O
its O
use O
as O
a O
stabilizer O
/ O
rigidifier O
of O
membranes O
, O
cholesteryl B
hemisuccinate I
, O
tris B
salt I
( O
CS B
) O
administration O
has O
also O
been O
shown O
to O
protect O
rats O
from O
the O
hepatotoxic O
effects O
of O
carbon B
tetrachloride I
( O
CCl4 B
) O
. O

In O
addition O
to O
its O
use O
as O
a O
stabilizer O
/ O
rigidifier O
of O
membranes O
, O
cholesteryl B
hemisuccinate I
, O
tris B
salt I
( O
CS B
) O
administration O
has O
also O
been O
shown O
to O
protect O
rats O
from O
the O
hepatotoxic O
effects O
of O
carbon B
tetrachloride I
( O
CCl4 B
) O
. O

In O
addition O
to O
its O
use O
as O
a O
stabilizer O
/ O
rigidifier O
of O
membranes O
, O
cholesteryl B
hemisuccinate I
, O
tris B
salt I
( O
CS B
) O
administration O
has O
also O
been O
shown O
to O
protect O
rats O
from O
the O
hepatotoxic O
effects O
of O
carbon B
tetrachloride I
( O
CCl4 B
) O
. O

To O
further O
our O
understanding O
of O
the O
mechanism O
of O
CS B
cytoprotection O
, O
we O
examined O
in O
rats O
and O
mice O
the O
protective O
abilities O
of O
CS B
and O
the O
non O
- O
hydrolyzable O
ether O
form O
of O
CS B
, O
gamma B
- I
cholesteryloxybutyric I
acid I
, O
tris B
salt I
( O
CSE B
) O
against O
acetaminophen B
- O
, O
adriamycin B
- O
, O
carbon B
tetrachloride I
- O
, O
chloroform B
- O
and O
galactosamine B
- O
induced O
toxicity O
. O

To O
further O
our O
understanding O
of O
the O
mechanism O
of O
CS B
cytoprotection O
, O
we O
examined O
in O
rats O
and O
mice O
the O
protective O
abilities O
of O
CS B
and O
the O
non O
- O
hydrolyzable O
ether O
form O
of O
CS B
, O
gamma B
- I
cholesteryloxybutyric I
acid I
, O
tris B
salt I
( O
CSE B
) O
against O
acetaminophen B
- O
, O
adriamycin B
- O
, O
carbon B
tetrachloride I
- O
, O
chloroform B
- O
and O
galactosamine B
- O
induced O
toxicity O
. O

A O
murine O
model O
of O
adenomyosis O
: O
the O
effects O
of O
hyperprolactinemia O
induced O
by O
fluoxetine B
hydrochloride I
, O
a O
selective O
serotonin B
reuptake O
inhibitor O
, O
on O
adenomyosis O
induction O
in O
Wistar O
albino O
rats O
. O

Neuroactive O
steroids B
protect O
against O
pilocarpine B
- O
and O
kainic B
acid I
- O
induced O
limbic O
seizures O
and O
status O
epilepticus O
in O
mice O
. O

Several O
structurally O
related O
metabolites O
of O
progesterone B
( O
3 B
alpha I
- I
hydroxy I
pregnane I
- I
20 I
- I
ones I
) O
and O
deoxycorticosterone B
( O
3 B
alpha I
- I
hydroxy I
pregnane I
- I
21 I
- I
diol I
- I
20 I
- I
ones I
) O
and O
their O
3 O
beta O
- O
epimers O
were O
evaluated O
for O
protective O
activity O
against O
pilocarpine B
- O
, O
kainic B
acid I
- O
and O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
- O
induced O
seizures O
in O
mice O
. O

Steroids B
with O
the O
5 O
alpha O
, O
3 O
alpha O
- O
or O
5 O
beta O
, O
3 O
alpha O
- O
configurations O
also O
produced O
a O
dose O
- O
dependent O
delay O
in O
the O
onset O
of O
limbic O
seizures O
induced O
by O
kainic B
acid I
( O
32 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
, O
but O
did O
not O
completely O
protect O
against O
the O
seizures O
. O

However O
, O
when O
a O
second O
dose O
of O
the O
steroid B
was O
administered O
1 O
hr O
after O
the O
first O
dose O
, O
complete O
protection O
from O
the O
kainic B
acid I
- O
induced O
limbic O
seizures O
and O
status O
epilepticus O
was O
obtained O
. O

We O
conclude O
that O
neuroactive O
steroids B
are O
highly O
effective O
in O
protecting O
against O
pilocarpine B
- O
and O
kainic B
acid I
- O
induced O
seizures O
and O
status O
epilepticus O
in O
mice O
, O
and O
may O
be O
of O
utility O
in O
the O
treatment O
of O
some O
forms O
of O
status O
epilepticus O
in O
humans O
. O

The O
attenuating O
effect O
of O
carteolol B
hydrochloride I
, O
a O
beta O
- O
adrenoceptor O
antagonist O
, O
on O
neuroleptic O
- O
induced O
catalepsy O
in O
rats O
. O

Effect O
of O
glyceryl B
trinitrate I
on O
the O
sphincter O
of O
Oddi O
spasm O
evoked O
by O
prostigmine B
- O
morphine B
administration O
. O

OBJECTIVE O
: O
In O
this O
study O
the O
effect O
of O
glyceryl B
trinitrate I
on O
the O
prostigmine B
- O
morphine B
- O
induced O
sphincter O
of O
Oddi O
spasm O
was O
evaluated O
in O
nine O
female O
patients O
with O
sphincter O
of O
Oddi O
dyskinesia O
. O

The O
entire O
procedure O
was O
repeated O
during O
glyceryl B
trinitrate I
infusion O
( O
Nitrolingual B
1 O
microg O
/ O
kg O
/ O
min O
for O
120 O
min O
) O
. O

Glyceryl B
trinitrate I
infusion O
completely O
normalized O
the O
prostigmine B
- O
morphine B
- O
induced O
alterations O
in O
these O
quantitative O
parameters O
( O
TmaX O
over O
the O
LP O
: O
11 O
. O
33 O
+ O
/ O
- O
1 O
. O
13 O
; O
over O
the O
HH O
: O
18 O
. O
88 O
+ O
/ O
- O
1 O
. O
48 O
; O
and O
over O
the O
CBD O
: O
36 O
. O
22 O
+ O
/ O
- O
1 O
. O
92 O
; O
and O
T1 O
/ O
2 O
over O
the O
LP O
: O
28 O
. O
21 O
+ O
/ O
- O
1 O
. O
83 O
; O
over O
the O
HH O
: O
33 O
. O
42 O
+ O
/ O
- O
3 O
. O
10 O
; O
and O
over O
the O
CBD O
: O
41 O
. O
66 O
+ O
/ O
- O
6 O
. O
33 O

) O
, O
suggesting O
an O
effective O
sphincter O
- O
relaxing O
effect O
of O
glyceryl B
trinitrate I
. O

CONCLUSION O
: O
These O
results O
provide O
the O
first O
evidence O
of O
the O
effectiveness O
of O
glyceryl B
trinitrate I
on O
the O
morphine B
- O
induced O
sphincter O
of O
Oddi O
spasm O
in O
humans O
. O

Since O
glyceryl B
trinitrate I
is O
able O
to O
overcome O
even O
the O
drastic O
effect O
of O
morphine B
, O
it O
might O
be O
of O
relevance O
in O
the O
treatment O
of O
sphincter O
of O
Oddi O
dyskinesia O
. O

Value O
of O
methylprednisolone B
in O
prevention O
of O
the O
arthralgia O
- O
myalgia O
syndrome O
associated O
with O
the O
total O
dose O
infusion O
of O
iron B
dextran I
: O
a O
double O
blind O
randomized O
trial O
. O

The O
safety O
and O
efficacy O
of O
total O
dose O
infusion O
( O
TDI O
) O
of O
iron B
dextran I
has O
been O
well O
documented O
. O

We O
conclude O
that O
125 O
mg O
i O
. O
v O
. O
MP B
should O
be O
given O
routinely O
before O
and O
after O
TDI O
of O
iron B
dextran I
. O

Epileptogenic O
activity O
of O
folic B
acid I
after O
drug O
induces O
SLE O
( O
folic B
acid I
and O
epilepsy O
) O

Epileptogenic O
activity O
of O
folic B
acid I
after O
drug O
induces O
SLE O
( O
folic B
acid I
and O
epilepsy O
) O

OBJECTIVE O
: O
To O
study O
the O
effect O
of O
folic B
acid I
- O
containing O
multivitamin O
supplementation O
in O
epileptic O
women O
before O
and O
during O
pregnancy O
in O
order O
to O
determine O
the O
rate O
of O
structural O
birth O
defects O
and O
epilepsy O
- O
related O
side O
effects O
. O

RESULTS O
: O
Of O
60 O
epileptic O
women O
with O
periconceptional O
folic B
acid I
( O
0 O
. O
8 O
mg O
) O
- O
containing O
multivitamin O
supplementation O
, O
no O
one O
developed O
epilepsy O
- O
related O
side O
effects O
during O
the O
periconception O
period O
. O

This O
22 O
- O
year O
- O
old O
epileptic O
woman O
was O
treated O
continuously O
by O
carbamazepine B
and O
a O
folic B
acid I
( O
1 O
mg O
) O
- O
containing O
multivitamin O
from O
the O
20th O
week O
of O
gestation O
. O

CONCLUSIONS O
: O
The O
epileptic O
pregnant O
patient O
' O
s O
autoimmune O
disease O
( O
probably O
drug O
- O
induced O
lupus O
) O
could O
damage O
the O
blood O
- O
brain O
barrier O
, O
therefore O
the O
therapeutic O
dose O
( O
> O
or O
= O
1 O
mg O
) O
of O
folic B
acid I
triggered O
a O
cluster O
of O
seizures O
. O

Physiological O
dose O
( O
< O
1 O
mg O
) O
of O
folic B
acid I
both O
in O
healthy O
and O
60 O
epileptic O
women O
, O
all O
without O
any O
autoimmune O
disease O
, O
did O
not O
increase O
the O
risk O
for O
epileptic O
seizures O
. O

